Clarivate Plc (CLVT), a provider of transformative intelligence, announced on Tuesday the launch of DRG Fusion, a pioneering platform aimed at advancing commercial analytics within the life sciences industry.
Developed by experts in clinical and data science, Fusion incorporates real-world data to equip biopharma and medtech companies with robust tools for navigating complex disease and competitive scenarios, thereby simplifying the management of raw data.
DRG Fusion tackles these challenges by offering a comprehensive array of market data and analytics sourced from integrated medical and pharmacy claims, in addition to other real-world data sources. This enables organizations in the life sciences sector to gain a clearer understanding of market dynamics and make well-informed decisions that foster innovation.
By delivering actionable insights, the platform empowers life sciences companies to contribute to a healthier future, thus accelerating progress in the industry.
Currently, Clarivate shares are trading at $5.01, reflecting a decrease of 2.15 percent or $0.11 on the New York Stock Exchange.
